Trials / Unknown
UnknownNCT03211572
The EMPOwER Study Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers
Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers: The EMPOwER Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 82 (estimated)
- Sponsor
- Ottawa Hospital Research Institute · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers
Detailed description
The clinical trial will be a prospective, two strata, non-blinded, single institution, Health Canada approved, Window of Opportunity trial with 2 weeks of pre-surgical endocrine therapy using either anastrozole or tamoxifen. Tissue from the initial biopsy and from surgery will be sent for Ki67 analysis using the NanoString® Assay.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tamoxifen | Participants will take endocrine therapy for 2 weeks prior to surgery. |
Timeline
- Start date
- 2017-08-01
- Primary completion
- 2018-08-01
- Completion
- 2018-08-01
- First posted
- 2017-07-07
- Last updated
- 2017-07-07
Source: ClinicalTrials.gov record NCT03211572. Inclusion in this directory is not an endorsement.